CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02243579
NCT02243579Phase 2Completed
CompareCT.gov

A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome

National Cancer Institute (NCI)·interventional·Posted Sep 18, 2014·Updated Sep 20, 2019

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Pembrolizumab for Recurrent Mycosis Fungoides and Sezary Syndrome and 8 related conditions. Completed, enrolled 24 participants across 8 sites.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IVB mycosis fungoides or Sezary syndrome that has returned after a period of improvement or has not responded to at least one type of treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 18, 2014
Enrollment StartOct 15, 2014
Primary CompletionJan 4, 2018
Study CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.8 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pembrolizumabbiological

Given IV